Market Research

Angioedema Treatment Market by Drugs Type (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Injections, Oral), End-User - Global Forecast 2024-2030

Best Price Guarantee Length Publisher Published Date SKU
from $4,749 183 Pages 360iResearch January, 2024 IRE18418311
Best Price Guarantee
Price from $4,749
Length 183 Pages
Publisher 360iResearch
Published Date January, 2024
SKU IRE18418311

Angioedema Treatment Market by Drugs Type (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Injections, Oral), End-User - Global Forecast 2024-2030


The Angioedema Treatment Market size was estimated at USD 4.69 billion in 2023 and expected to reach USD 5.50 billion in 2024, at a CAGR 17.28% to reach USD 14.32 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Angioedema Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Angioedema Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Angioedema Treatment Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., AMBOSS GmbH, Apotex Corp., Attune Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., Cipla USA Inc., CSL Behring GmbH, Fresenius Kabi USA, LLC, Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Lecturio GmbH, Merck & Co., Inc., Pharming Group N.V., Sanofi-Aventis Groupe S.A., Slayback Pharma LLC, Takeda Pharmaceutical Company Limited, and Viropharma Biologics LLC.

Market Segmentation & Coverage

This research report categorizes the Angioedema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drugs Type

C1 Esterase Inhibitor

Berinert
  • Cinryze
  • Haegarda
  • Ruconest
  • Kallikrein Inhibitor

    Kalbitor
  • Selective Bradykinin B2 Receptor Antagonist

    Firazyr
  • Route of Administration

    Injections
  • Oral
  • End-User

    Clinics
  • Hospitals
  • Research Organizations
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Angioedema Treatment Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Angioedema Treatment Market?
    3. What are the technology trends and regulatory frameworks in the Angioedema Treatment Market?
    4. What is the market share of the leading vendors in the Angioedema Treatment Market?
    5. Which modes and strategic moves are suitable for entering the Angioedema Treatment Market?


    Note: PDF & Excel + Online Access - 1 Year


    • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Angioedema Treatment Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Increasing cases of hereditary angioedema (HAE)
    5.1.1.2. Growing initiatives for improving awareness levels among the population
    5.1.1.3. Rising incidence of disease-related genetic mutations
    5.1.2. Restraints
    5.1.2.1. Misdiagnosis of angioedema
    5.1.3. Opportunities
    5.1.3.1. Government initiatives to facilitate faster diagnosis and provide optimal standards of treatment
    5.1.3.2. Development of advance therapeutics for hereditary angioedema disorders treatment
    5.1.4. Challenges
    5.1.4.1. High cost of the drugs used for treatment
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Angioedema Treatment Market, by Drugs Type
    6.1. Introduction
    6.2. C1 Esterase Inhibitor
    6.3.1. Berinert
    6.3.2. Cinryze
    6.3.3. Haegarda
    6.3.4. Ruconest
    6.3. Kallikrein Inhibitor
    6.4.1. Kalbitor
    6.4. Selective Bradykinin B2 Receptor Antagonist
    6.5.1. Firazyr
    7. Angioedema Treatment Market, by Route of Administration
    7.1. Introduction
    7.2. Injections
    7.3. Oral
    8. Angioedema Treatment Market, by End-User
    8.1. Introduction
    8.2. Clinics
    8.3. Hospitals
    8.4. Research Organizations
    9. Americas Angioedema Treatment Market
    9.1. Introduction
    9.2. Argentina
    9.3. Brazil
    9.4. Canada
    9.5. Mexico
    9.6. United States
    10. Asia-Pacific Angioedema Treatment Market
    10.1. Introduction
    10.2. Australia
    10.3. China
    10.4. India
    10.5. Indonesia
    10.6. Japan
    10.7. Malaysia
    10.8. Philippines
    10.9. Singapore
    10.10. South Korea
    10.11. Taiwan
    10.12. Thailand
    10.13. Vietnam
    11. Europe, Middle East & Africa Angioedema Treatment Market
    11.1. Introduction
    11.2. Denmark
    11.3. Egypt
    11.4. Finland
    11.5. France
    11.6. Germany
    11.7. Israel
    11.8. Italy
    11.9. Netherlands
    11.10. Nigeria
    11.11. Norway
    11.12. Poland
    11.13. Qatar
    11.14. Russia
    11.15. Saudi Arabia
    11.16. South Africa
    11.17. Spain
    11.18. Sweden
    11.19. Switzerland
    11.20. Turkey
    11.21. United Arab Emirates
    11.22. United Kingdom
    12. Competitive Landscape
    12.1. FPNV Positioning Matrix
    12.2. Market Share Analysis, By Key Player
    12.3. Competitive Scenario Analysis, By Key Player
    13. Competitive Portfolio
    13.1. Key Company Profiles
    13.1.1. Adverum Biotechnologies, Inc.
    13.1.2. AMBOSS GmbH
    13.1.3. Apotex Corp.
    13.1.4. Attune Pharmaceuticals, Inc.
    13.1.5. BioCryst Pharmaceuticals, Inc.
    13.1.6. Cipla USA Inc.
    13.1.7. CSL Behring GmbH
    13.1.8. Fresenius Kabi USA, LLC
    13.1.9. Ionis Pharmaceuticals, Inc.
    13.1.10. KalVista Pharmaceuticals, Inc.
    13.1.11. Lecturio GmbH
    13.1.12. Merck & Co., Inc.
    13.1.13. Pharming Group N.V.
    13.1.14. Sanofi-Aventis Groupe S.A.
    13.1.15. Slayback Pharma LLC
    13.1.16. Takeda Pharmaceutical Company Limited
    13.1.17. Viropharma Biologics LLC
    13.2. Key Product Portfolio
    14. Appendix
    14.1. Discussion Guide
    14.2. License & Pricing
    FIGURE 1. ANGIOEDEMA TREATMENT MARKET RESEARCH PROCESS
    FIGURE 2. ANGIOEDEMA TREATMENT MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANGIOEDEMA TREATMENT MARKET DYNAMICS
    FIGURE 7. ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2030 (%)
    FIGURE 8. ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUGS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
    FIGURE 10. ANGIOEDEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
    FIGURE 12. ANGIOEDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 14. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 16. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 22. ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

    $4,749
    $5,749
    $6,749
    $8,749

    Research Assistance

    US: 800.298.5699
    Int'l: +1.240.747.3093
    Live help
    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Other tasks

    Cookie Settings